Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HCC × Tirapazamine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 1 Hypoxia 1 HCC 1 Carcinoma, Hepatocellular 1

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06844357 2025-04-06

A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

Zhejiang Raygene Pharmaceuticals Co., Ltd

Phase 2/3 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡